Irisin levels increase after treatment in patients with newly diagnosed Hashimoto thyroiditis
Purpose Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin conce...
Saved in:
Published in | Journal of endocrinological investigation Vol. 42; no. 2; pp. 175 - 181 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.02.2019
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 1720-8386 0391-4097 1720-8386 |
DOI | 10.1007/s40618-018-0899-8 |
Cover
Abstract | Purpose
Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects.
Methods
The study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved.
Results
Serum irisin levels were significantly lower in the hypothyroid groups than the control group (
p
< 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (
r
= − 0.623,
p
< 0.001 and
r
= − 0.389,
p
= 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (
r
= 0.570,
p
< 0.001) was found. Serum CK levels decreased significantly after treatment (
p
< 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L,
p
< 0.001) when the hypothyroid patients were treated to achieve euthyroidism.
Conclusions
To the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto’s thyroiditis. |
---|---|
AbstractList | Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects.
The study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved.
Serum irisin levels were significantly lower in the hypothyroid groups than the control group (p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (r = - 0.623, p < 0.001 and r = - 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment (p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroid patients were treated to achieve euthyroidism.
To the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto's thyroiditis. PurposeIrisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects.MethodsThe study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved.ResultsSerum irisin levels were significantly lower in the hypothyroid groups than the control group (p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (r = − 0.623, p < 0.001 and r = − 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment (p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroid patients were treated to achieve euthyroidism.ConclusionsTo the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto’s thyroiditis. Purpose Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects. Methods The study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved. Results Serum irisin levels were significantly lower in the hypothyroid groups than the control group ( p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels ( r = − 0.623, p < 0.001 and r = − 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels ( r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment ( p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroid patients were treated to achieve euthyroidism. Conclusions To the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto’s thyroiditis. Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects.PURPOSEIrisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects.The study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved.METHODSThe study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved.Serum irisin levels were significantly lower in the hypothyroid groups than the control group (p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (r = - 0.623, p < 0.001 and r = - 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment (p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroid patients were treated to achieve euthyroidism.RESULTSSerum irisin levels were significantly lower in the hypothyroid groups than the control group (p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (r = - 0.623, p < 0.001 and r = - 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment (p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroid patients were treated to achieve euthyroidism.To the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto's thyroiditis.CONCLUSIONSTo the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto's thyroiditis. |
Author | Mizrak, S. Uc, Z. A. Gullu, S. Gorar, S. |
Author_xml | – sequence: 1 givenname: Z. A. surname: Uc fullname: Uc, Z. A. email: ziynetalp@yahoo.com organization: Department of Endocrinology, Usak University School of Medicine – sequence: 2 givenname: S. surname: Gorar fullname: Gorar, S. organization: Department of Endocrinology, Antalya Training and Research Hospital – sequence: 3 givenname: S. surname: Mizrak fullname: Mizrak, S. organization: Department of Biochemistry, Usak University School of Medicine – sequence: 4 givenname: S. surname: Gullu fullname: Gullu, S. organization: Department of Endocrinology, Ankara University School of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29777516$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1rGzEQhkVJaT7aH9BLEPTSy6Yaaa2PYwltEgj00h6LkLWzscKu5Ehyjf99ZZzQEEgPg95BzzsM856So5giEvIR2AUwpr6UnknQHduXNqbTb8gJKM46LbQ8eqaPyWkp94wJJbR6R465UUotQJ6Q3zc5lBDphH9wKjREn9EVpG6smGltTZ0x1vZB166GJgvdhrqiEbfTjg7B3cVUcKDXrqzCnGqidbXLKQyhhvKevB3dVPDD43tGfn3_9vPyurv9cXVz-fW280Lx2o2LXsmeLdxSoVROCsm9Uchx5IhsRHTGoZLgvJGGGc-BQ98ULAfNwffijHw-zF3n9LDBUu0cisdpchHTpljOepACQKmGfnqB3qdNjm07y0EDcCGFadT5I7VZzjjYdQ6zyzv7dLgGqAPgcyol42h9qO1AKdbswmSB2X1E9hCRZftqEVndnPDC-TT8fx5-8JTGxjvM_5Z-3fQXX9WjGw |
CitedBy_id | crossref_primary_10_12998_wjcc_v10_i4_1190 crossref_primary_10_1155_2021_3116068 crossref_primary_10_1007_s40618_020_01432_0 crossref_primary_10_1155_2019_3814687 crossref_primary_10_1007_s40619_022_01177_3 crossref_primary_10_1210_clinem_dgac575 crossref_primary_10_1016_j_biochi_2021_06_016 crossref_primary_10_1177_03000605211018422 crossref_primary_10_1177_2042018820917869 crossref_primary_10_1155_2020_2182735 |
Cites_doi | 10.1210/jc.2013-2312 10.1007/s40618-017-0690-2 10.1016/j.metabol.2012.09.002 10.1016/j.metabol.2015.01.001 10.1007/s40618-017-0661-7 10.1089/thy.1995.5.481 10.1016/j.peptides.2014.03.021 10.1089/thy.2016.0098 10.3109/07853890.2015.1085126 10.1016/j.metabol.2013.10.005 10.1016/j.peptides.2014.07.021 10.1111/cen.13527 10.3758/BF03193146 10.1590/2359-3997000000077 10.1016/j.peptides.2012.11.014 10.1371/journal.pone.0072858 10.1038/nrendo.2013.238 10.5603/EP.a2016.0030 10.1007/s00421-014-2922-x 10.1016/j.metabol.2013.02.002 10.1089/thy.2007.0256 10.1210/jc.2009-0782 10.1038/nature10777 10.1371/journal.pone.0060563 10.1155/2012/960363 |
ContentType | Journal Article |
Copyright | Italian Society of Endocrinology (SIE) 2018 Copyright Springer Nature B.V. 2019 |
Copyright_xml | – notice: Italian Society of Endocrinology (SIE) 2018 – notice: Copyright Springer Nature B.V. 2019 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
DOI | 10.1007/s40618-018-0899-8 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1720-8386 |
EndPage | 181 |
ExternalDocumentID | 29777516 10_1007_s40618_018_0899_8 |
Genre | Journal Article |
GroupedDBID | --- -EM 0R~ 203 4.4 406 5GY 5RE 8YF 96X AACDK AAHNG AAJBT AAJKR AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAZMS ABAKF ABDZT ABECU ABFTV ABHLI ABIPD ABJNI ABJOX ABKCH ABMQK ABPLI ABQBU ABTEG ABTKH ABTMW ABXPI ACAOD ACDTI ACGFS ACHSB ACKNC ACMLO ACOKC ACPIV ACPRK ACZOJ ADHHG ADINQ ADJJI ADKNI ADKPE ADURQ ADYFF ADZKW AEFQL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETCA AEVLU AEXYK AFBBN AFQWF AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AIAKS AIGIU AILAN AITGF AJRNO AJZVZ AKLTO AKMHD ALFXC ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AMYQR ANMIH ASPBG AUKKA AVWKF AXYYD BGNMA CSCUP DNIVK DPUIP EBLON EBS EIOEI EJD ESBYG F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FYJPI GGCAI GGRSB GJIRD GQ7 HG6 HRMNR I0C IKXTQ IMOTQ ITM IWAJR J-C JBSCW JZLTJ KOV LLZTM M4Y NPVJJ NQJWS NU0 O93 O9G O9J P2P PT4 RLLFE ROL RSV SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE TSG U9L UG4 UOJIU UTJUX UZXMN VFIZW W48 Z7U Z83 Z87 ZMTXR ZOVNA .GJ 53G 8RF AAEWM AAIAL AANXM AAYTO AAYXX ABBRH ABDBE ABFSG ACSTC ACUDM AEBTG AEKMD AEODN AEZWR AFDZB AFHIU AFOHR AHPBZ AHSBF AHWEU AI. AIXLP AJBLW ATHPR AYFIA AZFZN CITATION GRRUI RHV SCLPG SDE VH1 ZGI ZXP CGR CUY CVF ECM EIF NPM ABRTQ K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c372t-f5476405ab7e67a6362c97e2ef2ee0feea9ae761ac96909c212146901bd821c43 |
IEDL.DBID | AGYKE |
ISSN | 1720-8386 0391-4097 |
IngestDate | Thu Sep 04 19:48:33 EDT 2025 Wed Sep 17 13:51:20 EDT 2025 Thu Apr 03 07:05:01 EDT 2025 Thu Apr 24 23:10:42 EDT 2025 Tue Jul 01 02:10:46 EDT 2025 Fri Feb 21 02:32:48 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Overt hypothyroidism Irisin Hypothyroidism Hashimoto thyroiditis |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c372t-f5476405ab7e67a6362c97e2ef2ee0feea9ae761ac96909c212146901bd821c43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 29777516 |
PQID | 2181123639 |
PQPubID | 2043718 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_2041631177 proquest_journals_2181123639 pubmed_primary_29777516 crossref_citationtrail_10_1007_s40618_018_0899_8 crossref_primary_10_1007_s40618_018_0899_8 springer_journals_10_1007_s40618_018_0899_8 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-02-01 |
PublicationDateYYYYMMDD | 2019-02-01 |
PublicationDate_xml | – month: 02 year: 2019 text: 2019-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: Italy – name: Heidelberg |
PublicationSubtitle | Official Journal of Italian Society of Endocrinology (SIE) |
PublicationTitle | Journal of endocrinological investigation |
PublicationTitleAbbrev | J Endocrinol Invest |
PublicationTitleAlternate | J Endocrinol Invest |
PublicationYear | 2019 |
Publisher | Springer International Publishing Springer Nature B.V |
Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
References | Panagiotou, Pazaitou-Panayiotou, Paschou, Komninou, Kalogeris, Vryonidou, Mantzoros (CR14) 2016; 26 Roberts, Bayless, Company, Jenkins, Padilla, Childs, Martin, Dalbo, Booth, Rector, Laughlin (CR19) 2013; 62 Faul, Erdfelder, Lang, Buchner (CR17) 2007; 39 Ellefsen, Vikmoen, Slettaløkken, Whist, Nygaard, Hollan, Rauk, Vegge, Strand, Raastad, Rønnestad (CR22) 2014; 114 Aydin (CR7) 2014; 56 Ates, Altay, Topcuoglu, Yilmaz (CR12) 2016; 60 Gouni-Berthold, Berthold, Huh, Berman, Spenrath, Krone, Mantzoros (CR21) 2013 Gallo, Piantanida, Veronesi, Lai, Sassi, Lombardi, Masiello, Premoli, Bianconi, Cusini, Rosetti, Tanda, Toniolo, Ferrario, Bartalena (CR25) 2017; 40 Moon, Mantzoros (CR5) 2014; 63 Silva (CR1) 1995; 5 Lapa, Maya, Wagner, Arias-Loza, Werner, Herrmann, Higuchi (CR9) 2015; 47 Roca-Rivada, Castelao, Senin, Landrove, Baltar, Belen Crujeiras, Seoane, Casanueva, Pardo (CR6) 2013; 8 Zybek-Kocik, Sawicka-Gutaj, Wrotkowska, Sowinski, Ruchala (CR15) 2016; 67 Salvatore, Simonides, Dentice, Zavacki, Larsen (CR11) 2014; 10 Visser, Heemstra, Swagemakers, Ozgur, Corssmit, Burggraaf, van Ijcken, van der Spek, Smit, Visser (CR10) 2009; 94 Stengel, Hofmann, Goebel-Stengel, Elbelt, Kobelt, Klapp (CR20) 2013; 39 Samy, Ismail, Nassra (CR23) 2015; 64 Bostrom, Wu, Jedrychowski, Korde, Ye, Lo, Rasbach, Bostrom, Choi, Long, Kajimura, Zingaretti, Vind, Tu, Cinti, Hojlund, Gygi, Spiegelman (CR3) 2012; 481 Lahesmaa, Orava, Schalin-Jantti, Soinio, Hannukainen, Noponen, Kirjavainen, Iida, Kudomi, Enerback, Virtanen, Nuutila (CR8) 2014; 99 Huh, Panagiotou, Mougios, Brinkoetter, Vamvini, Schneider, Mantzoros (CR4) 2012; 61 Sforza, Rosenfarb, Rujelman, RosmarinM, Frigerio, Fossati, Caruso, Faingold, Meroño, Brenta (CR18) 2017; 40 Simonides, van Hardeveld (CR2) 2008; 18 Zybek-Kocik, Sawicka-Gutaj, Szczepanek-Parulska, Andrusiewicz, Waligórska-Stachura, Białas, Krauze, Guzik, Skrobisz, Ruchała (CR16) 2017 Baird, Graham, Baker, Bickerstaff (CR24) 2012 Ruchala, Zybek, Szczepanek-Parulska (CR13) 2014; 60 WE Visser (899_CR10) 2009; 94 MD Roberts (899_CR19) 2013; 62 MF Baird (899_CR24) 2012 N Sforza (899_CR18) 2017; 40 I Gouni-Berthold (899_CR21) 2013 C Lapa (899_CR9) 2015; 47 D Gallo (899_CR25) 2017; 40 M Lahesmaa (899_CR8) 2014; 99 F Faul (899_CR17) 2007; 39 JE Silva (899_CR1) 1995; 5 JY Huh (899_CR4) 2012; 61 A Zybek-Kocik (899_CR16) 2017 A Stengel (899_CR20) 2013; 39 D Salvatore (899_CR11) 2014; 10 M Ruchala (899_CR13) 2014; 60 DM Samy (899_CR23) 2015; 64 P Bostrom (899_CR3) 2012; 481 A Roca-Rivada (899_CR6) 2013; 8 G Panagiotou (899_CR14) 2016; 26 HS Moon (899_CR5) 2014; 63 WS Simonides (899_CR2) 2008; 18 S Aydin (899_CR7) 2014; 56 A Zybek-Kocik (899_CR15) 2016; 67 S Ellefsen (899_CR22) 2014; 114 I Ates (899_CR12) 2016; 60 |
References_xml | – volume: 99 start-page: E28 year: 2014 end-page: E35 ident: CR8 article-title: Hyperthyroidism increases brown fat metabolism in humans publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2013-2312 – volume: 40 start-page: 1303 year: 2017 end-page: 1310 ident: CR18 article-title: Hypothyroidism in hospitalized elderly patients: a sign of worse prognosis publication-title: J Endocrinol Invest doi: 10.1007/s40618-017-0690-2 – volume: 61 start-page: 1725 year: 2012 end-page: 1738 ident: CR4 article-title: FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise publication-title: Metab Clin Exp doi: 10.1016/j.metabol.2012.09.002 – volume: 64 start-page: 804 issue: 7 year: 2015 end-page: 813 ident: CR23 article-title: Circulating irisin concentrations in rat models of thyroid dysfunction—effect of exercise publication-title: Metabolism doi: 10.1016/j.metabol.2015.01.001 – volume: 40 start-page: 1099 year: 2017 end-page: 1106 ident: CR25 article-title: Physical performance in newly diagnosed hypothyroidism: a pilot study publication-title: J Endocrinol Invest doi: 10.1007/s40618-017-0661-7 – volume: 5 start-page: 481 year: 1995 end-page: 492 ident: CR1 article-title: Thyroid hormone control of thermogenesis and energy balance publication-title: Thyroid doi: 10.1089/thy.1995.5.481 – volume: 56 start-page: 94 year: 2014 end-page: 110 ident: CR7 article-title: Three new players in energy regulation: preptin, adropin and irisin publication-title: Peptides doi: 10.1016/j.peptides.2014.03.021 – volume: 26 start-page: 1039 issue: 8 year: 2016 end-page: 1045 ident: CR14 article-title: Changes of thyroid hormone levels within the normal and/or subclinical hyper- or hypothyroid range do not affect circulating irisin levels in humans publication-title: Thyroid doi: 10.1089/thy.2016.0098 – volume: 47 start-page: 538 year: 2015 end-page: 545 ident: CR9 article-title: Activation of brown adipose tissue in hypothyroidism publication-title: Ann Med doi: 10.3109/07853890.2015.1085126 – volume: 63 start-page: 188 year: 2014 end-page: 193 ident: CR5 article-title: Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines publication-title: Metab Clin Exp doi: 10.1016/j.metabol.2013.10.005 – volume: 60 start-page: 51 year: 2014 end-page: 55 ident: CR13 article-title: Serum irisin levels and thyroid function-newly discovered association publication-title: Peptides doi: 10.1016/j.peptides.2014.07.021 – year: 2017 ident: CR16 article-title: The association between irisin and muscle metabolism in different thyroid disorders publication-title: Clin Endocrinol doi: 10.1111/cen.13527 – volume: 39 start-page: 175 issue: 2 year: 2007 end-page: 191 ident: CR17 article-title: G*Power 3: a flexible statistical power analysis program for the social, behavioural, and biomedical sciences publication-title: Behav Res Methods doi: 10.3758/BF03193146 – volume: 60 start-page: 95 year: 2016 end-page: 100 ident: CR12 article-title: Circulating levels of irisin is elevated in hypothyroidism, a case-control study publication-title: Arch Endocrinol Metab doi: 10.1590/2359-3997000000077 – volume: 39 start-page: 125 year: 2013 end-page: 130 ident: CR20 article-title: Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity—correlation with body mass index publication-title: Peptides doi: 10.1016/j.peptides.2012.11.014 – year: 2013 ident: CR21 article-title: Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo publication-title: PLoS ONE doi: 10.1371/journal.pone.0072858 – volume: 10 start-page: 206 year: 2014 end-page: 214 ident: CR11 article-title: Thyroid hormones and skeletal muscle—new insights and potential implications publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2013.238 – volume: 67 start-page: 476 issue: 5 year: 2016 end-page: 480 ident: CR15 article-title: Time-dependent irisin concentration changes in patients affected by overt hypothyroidism publication-title: Endokrynol Pol doi: 10.5603/EP.a2016.0030 – volume: 114 start-page: 1875 issue: 9 year: 2014 end-page: 1888 ident: CR22 article-title: Irisin and FNDC5: effects of 12-week strength training, and relations to muscle phenotype and body mass composition in untrained women publication-title: Eur J Appl Physiol doi: 10.1007/s00421-014-2922-x – volume: 62 start-page: 1052 year: 2013 end-page: 1056 ident: CR19 article-title: Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats publication-title: Metabolism doi: 10.1016/j.metabol.2013.02.002 – volume: 18 start-page: 205e216 year: 2008 ident: CR2 article-title: Thyroid hormone as a determinant of metabolic and contractile phenotype of skeletal muscle publication-title: Thyroid doi: 10.1089/thy.2007.0256 – volume: 94 start-page: 3487 year: 2009 end-page: 3496 ident: CR10 article-title: Physiological thyroid hormone levels regulate numerous skeletal muscle transcripts publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2009-0782 – volume: 481 start-page: 463 year: 2012 end-page: 468 ident: CR3 article-title: A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis publication-title: Nature doi: 10.1038/nature10777 – volume: 8 start-page: e60563 year: 2013 ident: CR6 article-title: FNDC5/irisin is not only a myokine but also an adipokine publication-title: PLoS ONE doi: 10.1371/journal.pone.0060563 – year: 2012 ident: CR24 article-title: Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery publication-title: J Nutr Metab doi: 10.1155/2012/960363 – volume: 47 start-page: 538 year: 2015 ident: 899_CR9 publication-title: Ann Med doi: 10.3109/07853890.2015.1085126 – volume: 63 start-page: 188 year: 2014 ident: 899_CR5 publication-title: Metab Clin Exp doi: 10.1016/j.metabol.2013.10.005 – volume: 60 start-page: 51 year: 2014 ident: 899_CR13 publication-title: Peptides doi: 10.1016/j.peptides.2014.07.021 – volume: 39 start-page: 125 year: 2013 ident: 899_CR20 publication-title: Peptides doi: 10.1016/j.peptides.2012.11.014 – volume: 26 start-page: 1039 issue: 8 year: 2016 ident: 899_CR14 publication-title: Thyroid doi: 10.1089/thy.2016.0098 – volume: 114 start-page: 1875 issue: 9 year: 2014 ident: 899_CR22 publication-title: Eur J Appl Physiol doi: 10.1007/s00421-014-2922-x – volume: 61 start-page: 1725 year: 2012 ident: 899_CR4 publication-title: Metab Clin Exp doi: 10.1016/j.metabol.2012.09.002 – volume: 481 start-page: 463 year: 2012 ident: 899_CR3 publication-title: Nature doi: 10.1038/nature10777 – volume: 8 start-page: e60563 year: 2013 ident: 899_CR6 publication-title: PLoS ONE doi: 10.1371/journal.pone.0060563 – volume: 39 start-page: 175 issue: 2 year: 2007 ident: 899_CR17 publication-title: Behav Res Methods doi: 10.3758/BF03193146 – volume: 62 start-page: 1052 year: 2013 ident: 899_CR19 publication-title: Metabolism doi: 10.1016/j.metabol.2013.02.002 – volume: 99 start-page: E28 year: 2014 ident: 899_CR8 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2013-2312 – volume: 40 start-page: 1303 year: 2017 ident: 899_CR18 publication-title: J Endocrinol Invest doi: 10.1007/s40618-017-0690-2 – year: 2012 ident: 899_CR24 publication-title: J Nutr Metab doi: 10.1155/2012/960363 – volume: 94 start-page: 3487 year: 2009 ident: 899_CR10 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2009-0782 – volume: 67 start-page: 476 issue: 5 year: 2016 ident: 899_CR15 publication-title: Endokrynol Pol doi: 10.5603/EP.a2016.0030 – volume: 40 start-page: 1099 year: 2017 ident: 899_CR25 publication-title: J Endocrinol Invest doi: 10.1007/s40618-017-0661-7 – volume: 5 start-page: 481 year: 1995 ident: 899_CR1 publication-title: Thyroid doi: 10.1089/thy.1995.5.481 – year: 2017 ident: 899_CR16 publication-title: Clin Endocrinol doi: 10.1111/cen.13527 – year: 2013 ident: 899_CR21 publication-title: PLoS ONE doi: 10.1371/journal.pone.0072858 – volume: 18 start-page: 205e216 year: 2008 ident: 899_CR2 publication-title: Thyroid doi: 10.1089/thy.2007.0256 – volume: 10 start-page: 206 year: 2014 ident: 899_CR11 publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2013.238 – volume: 64 start-page: 804 issue: 7 year: 2015 ident: 899_CR23 publication-title: Metabolism doi: 10.1016/j.metabol.2015.01.001 – volume: 56 start-page: 94 year: 2014 ident: 899_CR7 publication-title: Peptides doi: 10.1016/j.peptides.2014.03.021 – volume: 60 start-page: 95 year: 2016 ident: 899_CR12 publication-title: Arch Endocrinol Metab doi: 10.1590/2359-3997000000077 |
SSID | ssj0037387 |
Score | 2.2745614 |
Snippet | Purpose
Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a... Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound... PurposeIrisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 175 |
SubjectTerms | Adult Autoantibodies Creatine Creatine kinase Creatine Kinase - blood Endocrinology Female Fibronectins - blood Hashimoto Disease - blood Hashimoto Disease - drug therapy Hormone Replacement Therapy Humans Hypothyroidism Male Medicine Medicine & Public Health Metabolic Diseases Metabolism Original Article Patients Skeletal muscle Thyroid Thyroid Function Tests Thyroid gland Thyroiditis Thyrotropin - blood Thyroxine Thyroxine - blood Thyroxine - therapeutic use Treatment Outcome |
Title | Irisin levels increase after treatment in patients with newly diagnosed Hashimoto thyroiditis |
URI | https://link.springer.com/article/10.1007/s40618-018-0899-8 https://www.ncbi.nlm.nih.gov/pubmed/29777516 https://www.proquest.com/docview/2181123639 https://www.proquest.com/docview/2041631177 |
Volume | 42 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1720-8386 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0037387 issn: 1720-8386 databaseCode: AFBBN dateStart: 19970101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1720-8386 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0037387 issn: 1720-8386 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwED90A_HF74_qHBF8Uir9WtM8TtkcyvbkYD5IabIUhqOTdXvQv967folOBaF9StKmySX3u97ldwAXRDkVoeFhuiTBnnI8U0hHZVGECLfxypiY-gO_N_TuR61RcY47LaPdS5dktlNXh91I9VDgFTEqC2EG61BvkX1Sg3r77umhU27AxNXDSwfmTw2_qqAVXLniE81UTXcbHstO5hEmL9fLhbxW79_4G__5FTuwVUBP1s5lZRfWdLIHG_3Cub4Pz5RtfpKwKcURpWySEKBMNcvSiLMqIh0LWMHGmjL6jcsQmU_f2DgP2tNj1qMETSgCM4ZSMJ9NxsSbdADDbufxtmcW2RdM5XJnYcYtj_sI5yLJtc8jHzWdElw7Ona0tmKtideb-3akBFrYQqEOtMnWtuU4cGzluYdQS2aJPgYmsL5PLDCWCjwd29LyYzfwlNRaSotHBljlhISqoCanDBnTsCJVzoYttOjGYQsDAy6rJq85L8dflRvlLIfFEk1DwjZEPeMKA86rYlxc5DGJEj1bYh2L8Cr5tQ04yqWjepuDyJm3bN-Aq3KmPx_-a1dO_lX7FDYRoIk8SrwBtcV8qc8QBC1kE4W-e3MzaBbC_wGgsP63 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JTsMwEB1BKwEX9iWsRuIESpXFjeNjhYCylFOR4ICi2HWkiipFpD3A1zOTDbFKSMnJ48Sxx57nzPgNwBFRTsW48bB90mCuPW5L5ek8ihDhNl45E1PvNuje8av79n15jjurot0rl2S-UteH3cj0UOAVMSpLaYez0ORuGPIGNDsXD9dn1QJMXD2icmD-VPGzCfqGK7_5RHNTc74E_aqRRYTJU2s6US399oW_8Z9fsQyLJfRknUJXVmDGpKsw1yud62vwSNnmhykbURxRxoYpAcrMsDyNOKsj0rGAlWysGaPfuAyR-eiVDYqgPTNgXUrQhCowZqgFL-PhgHiT1uHu_Kx_2rXL7Au29oU3sZM2FwHCuVgJE4g4QEunpTCeSTxjnMQY4vUWgRtriTtsqdEGurTXdtUg9FzN_Q1opOPUbAGTKB8QC4yjQ24SVzlB4odcK2OUckRsgVMNSKRLanLKkDGKalLlvNsih27stii04Liu8lzwcvwlvFuNclRO0SwibEPUM7604LAuxslFHpM4NeMpyjiEV8mvbcFmoR312zxEzqLtBhacVCP98fBfm7L9L-kDmO_2ezfRzeXt9Q4sIFiTRcT4LjQmL1Ozh4BoovbLCfAOxnkAOw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFH7oCOLFfalrBE9Ktds0zVHUcVzxoKAHqU2awuDQEds56K_3vW7iCiK0pyZtmrz0fen78j2ALZKcinDhYbpkwZ5yPFNIRxUsQoTbeBRKTBeXfvfGO71t31Z5TrOa7V6HJMs9DaTSlOZ7T3Gy12x8IzdEJCxSVxbCDEZhzEPn1m7B2P7x3dlR_TEm3R5eBzO_q_jRHX3BmF_io4Xb6UzBQ93gkm3yuDvM5a56_aTl-I83mobJCpKy_dKGZmBEp7MwflEF3efgnrLQ91LWJ35RxnopAc1MsyK9OGuY6niBVSqtGaPfuwwRe_-FxSWZT8esS4mb0DQGDK3jedCLSU9pHm46R9cHXbPKymAqlzu5mbQ97iPMiyTXPo989IBKcO3oxNHaSrQmvW_u25ESuPIWCn2jTWtwW8aBYyvPXYBWOkj1EjCB5X1Sh7FU4OnElpafuIGnpNZSWjwywKoHJ1SVZDllzuiHjdhy0W2hRSd2WxgYsN1UeSr1On4rvFqPeFhN3SwkzEOSNK4wYLO5jJOOIilRqgdDLGMRjqV4twGLpaU0T3MQUfO27RuwU4_6-81_bMryn0pvwPjVYSc8P7k8W4EJxHCiJJKvQit_Huo1xEm5XK_mwhsvRwkW |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Irisin+levels+increase+after+treatment+in+patients+with+newly+diagnosed+Hashimoto+thyroiditis&rft.jtitle=Journal+of+endocrinological+investigation&rft.au=Uc%2C+Z+A&rft.au=Gorar%2C+S&rft.au=Mizrak%2C+S&rft.au=Gullu%2C+S&rft.date=2019-02-01&rft.issn=1720-8386&rft.eissn=1720-8386&rft.volume=42&rft.issue=2&rft.spage=175&rft_id=info:doi/10.1007%2Fs40618-018-0899-8&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1720-8386&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1720-8386&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1720-8386&client=summon |